MK-677 vs Tesofensine

These sit in different classes. MK-677 is a growth hormone secretagogue; Tesofensine is a metabolic compound. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control. On this site's goal weighting — an editorial priority score, not a measure of effect size — MK-677 rates 5/5 for appetite control and Tesofensine rates 5/5. Outside that overlap they diverge: MK-677 also carries weight for recovery and sleep and muscle growth, Tesofensine for fat loss.

One trap on this pairing: both score highly for appetite control, but they push it in opposite directions. MK-677 is flagged in this dataset as moving it the wrong way, while Tesofensine carries no such flag. A goal weight measures how hard a compound acts on something, not which way it acts — so this is the one place on the page where a tie is not a tie.

Tesofensine sits one step firmer: approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. MK-677 has controlled human trials behind it, without an approval — never approved, and trials flagged higher fasting glucose. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

The kinetics are roughly 9× apart — 9.2 days for Tesofensine against 24 h for MK-677 — and yet both are dosed once daily. That schedule is convention rather than clearance, which is worth knowing before you assume the two behave the same way between doses.

Committed time differs: MK-677 runs 16 weeks, Tesofensine runs 24 weeks.

The contraindication lists are not the same: MK-677 flags active malignancy, which Tesofensine does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

MK-677 is rated intermediate here and Tesofensine advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.